Be the first person to write a business review for Huntingdon Life Sciences Limited

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

IGI Laboratories, Inc. was founded in 1977 and is headquartered in Buena, New Jersey. IGI Laboratories, Inc. engages in the development, manufacture, filling, and packaging of topical, semi solid, and liquid products for pharmaceutical, cosmeceutical, and cosmetic companies. The company focuses on the commercialization of its licensed Novasome encapsulation technology for skin care/treatment products. It licenses the Novasome encapsulation technology from Novavax, Inc. for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals, as well as the processes for making the same. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008.

Illumina was founded in 1998 and is headquartered in San Diego, California. Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include Genome Analyzer II, an instrument for high-throughput sequencing using Illumina sequencing by synthesis technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company's consumables comprise Standard Sequencing Kit, a reagent used for sequencing by synthesis chemistry on the Genome Analyzer; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200—500 kb insert paired-end reads; InfiniumHD Whole-Genome BeadChips comprising Human1M-Duo, Human610-Quad, Human660W-Quad, and HumanCytoSNP-12, which are multi-sample DNA analysis microarrays that interrogate up to 1.2 million markers per sample; iSelect Custom Genotyping BeadChips that are customer designable SNP genotyping arrays for 6,000 to 200,000 markers; and Whole-Genome Gene Expression BeadChips, which are multi-sample expression profiling arrays with up-to-date content for human, mouse, and rat.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.